Sign In

William E Carson, III MD

William E Carson, III MD
ProfessorCollege of Medicinewilliam.carson@osumc.eduwebsite
N911 Doan Hall 410 W 10th Avenue Columbus OH 43210
Phone:614-292-5819Alternate Phone:614-293-6306Fax: 614-688-4366
  • Innate Immunity

General Research Interest

Tumor immunology

Research Description

Dr. Carson is a surgical oncologist with clinical interests in breast cancer, melanoma and general cancer surgery. His primary research focus is the immunotherapy of tumors, which can be thought of as using drugs and other treatments to boost the human immune system's innate ability to fight tumor cells.  Dr. Carson came to Ohio State in 1997 from Roswell Park Cancer Institute in Buffalo. NY.  He is a professor of surgery and of Medical Microbiology and Immunology. In addition to his role as Associate Director for Clinical Research in the OSU Comprehensive Cancer Center (OSUCCC), he serves as co-leader of the OSUCCC's Immunology Program.  He has a number of active cancer research grants which look at novel immunological approaches to the treatment of advanced malignant melanoma, the most deadly form of skin cancer.

Transinstitutional Work

Dr. Carson collaborates with OSU investigators who are investigating the effects of stress on immunity, nanotechnology, and experimental therapeutics.  He is on the board of directors for the International Society for the Biological Therapy of Cancer and serves on the NCCN (National Comprehensive Cancer Network) advisory board for Melanoma.

Current Publications

  • Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE 3rd, Daud A, Dimaio D, Fleming MD, Guild V, Halpern AC, Hodi FS Jr, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, McMillian N, Ho MMelanoma, version 2.2013: featured updates to the NCCN guidelines.J Natl Compr Canc Netw 11(4) 395-407 4/1/2013
  • Khrizman P, Niland JC, Ter Veer A, Milne D, Bullard Dunn K, Carson WE 3rd, Engstrom PF, Shibata S, Skibber JM, Weiser MR, Schrag D, Benson AB 3rdPostoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis.J Clin Oncol 31(1) 30-8 1/1/2013
  • Markowitz J, Carson WE 3rdReview of S100A9 biology and its role in cancer.Biochim Biophys Acta 1835(1) 100-9 1/1/2013
  • Foy KC, Miller MJ, Moldovan N, Carson WE, Kaumaya PPCorrection to: Foy KC, Miller MJ, Moldovan N, Carson III WE, Kaumaya PTP. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. OncoImmunology 201Oncoimmunology 2(1) e23914 1/1/2013
  • Lindgren ME, Fagundes CP, Alfano CM, Povoski SP, Agnese DM, Arnold MW, Farrar WB, Yee LD, Carson WE, Schmidt CR, Kiecolt-Glaser JKBeta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients.Psychooncology in press 12/17/2012
  • Tarr AJ, Powell ND, Reader BF, Bhave NS, Roloson AL, Carson WE 3rd, Sheridan JFβ-Adrenergic receptor mediated increases in activation and function of natural killer cells following repeated social disruption.Brain Behav Immun 26(8) 1226-38 11/1/2012
  • Foy KC, Miller MJ, Moldovan N, Bozanovic T, Carson Iii WE, Kaumaya PTImmunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer.Oncoimmunology 1(7) 1004-1016 10/1/2012
  • Foy KC, Miller MJ, Moldovan N, Carson Iii WE, Kaumaya PTCombined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo.Oncoimmunology 1(7) 1048-1060 10/1/2012
  • Luedke E, Jaime-Ramirez AC, Bhave N, Roda J, Carson WE 3rdCetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.Surgery 152(3) 431-40 9/1/2012
  • Abdel-Rahman MH, Cebulla CM, Verma V, Christopher BN, Carson WE 3rd, Olencki T, Davidorf FHMonosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival.Exp Eye Res 100 26-31 7/1/2012
  • Luedke E, Cristina Jaime-Ramirez A, Bhave N, Carson WE 3rdMonoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.J Immunother 35(5) 367-73 6/1/2012
  • Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE 3rd, Daud A, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS Jr, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MMMelanoma.J Natl Compr Canc Netw 10(3) 366-400 3/1/2012
  • Fagundes CP, Glaser R, Alfano CM, Bennett JM, Povoski SP, Lipari AM, Agnese DM, Yee LD, Carson WE 3rd, Farrar WB, Malarkey WB, Kiecolt-Glaser JKFatigue and herpesvirus latency in women newly diagnosed with breast cancer.Brain Behav Immun 26(3) 394-400 3/1/2012
  • Wells-Di Gregorio SM, Carpenter KM, Dorfman CS, Yang HC, Simonelli LE, Carson, III WEImpact of breast cancer recurrence and cancer-specific stress on spouse health and immune function.Brain Behav Immun 26(2) 228-33 2/1/2012
  • Wasserman J, Diese L, Vangundy Z, London C, Carson WE, Papenfuss TLSuppression of canine myeloid cells by soluble factors from cultured canine tumor cells.Vet Immunol Immunopathol 145(1-2) 420-30 1/15/2012
  • Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE 3rd, O'Day SJBEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.J Clin Oncol 30(1) 34-41 1/1/2012
  • Fagundes CP, Bennett JM, Alfano CM, Glaser R, Povoski SP, Lipari AM, Agnese DM, Yee LD, Carson WE, Farrar WB, Malarkey WB, Chen M, Kiecolt-Glaser JKSocial support and socioeconomic status interact to predict Epstein-Barr virus latency in women awaiting diagnosis or newly diagnosed with breast cancer.Health Psychol 31(1) 11-9 1/1/2012
  • Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Hakansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Nelief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis MLDefining the critical hurdles in cancer immunotherapy.J Transl Med 9(1) 214 12/14/2011
  • Terando AM, Carson WE 3rdIndividualized local treatment strategies for in-transit melanoma.Oncology (Williston Park) 25(14) 1355, 1360 12/1/2011
  • Grignol V, Fairchild ET, Zimmerer JM, Lesinski GB, Walker MJ, Magro CM, Kacher JE, Karpa VI, Clark J, Nuovo G, Lehman A, Volinia S, Agnese DM, Croce CM, Carson WE 3rdmiR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions.Br J Cancer 105(7) 1023-9 9/27/2011
  • Mundy-Bosse BL, Young GS, Bauer T, Binkley E, Bloomston M, Bill MA, Bekaii-Saab T, Carson WE 3rd, Lesinski GBDistinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.Cancer Immunol Immunother 60(9) 1269-79 9/1/2011
  • Guenterberg KD, Lesinski GB, Mundy-Bosse BL, Karpa VI, Jaime-Ramirez AC, Wei L, Carson WE 3rdEnhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4⁺ and CD8⁺ T cells.Cancer Immunol Immunother 60(9) 1281-8 9/1/2011
  • Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy P, Guenterberg K, Kondadasula SV, Ray Chaudhury A, La Perle KM, Kreiner M, Young GS, Guttridge DC, Carson WEMyeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.Cancer Res 71(15) 5101-10 8/1/2011
  • Grignol VP, Olencki T, Relekar K, Taylor C, Kibler A, Kefauver C, Wei L, Walker MJ, Chen HX, Kendra K, Carson WEA phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.J Immunother 34(6) 509-15 7/1/2011